Suven Life Sciences' Q2 FY 2025-26 Quarterly Results

Result Summary

• Suven Life Sciences Ltd reported a 90.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 28.9%.
• Its expenses for the quarter were up by 51.9% QoQ and 45.8% YoY.
• The net profit increased 50.1% QoQ and increased 55.7% YoY.
• The earnings per share (EPS) of Suven Life Sciences Ltd declined at 3.48 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Suven Life Sciences Ltd is a biopharmaceutical company focused on drug discovery and development. The company operates primarily within the pharmaceutical industry, with its main products and services revolving around the development of therapeutic solutions for central nervous system disorders. Key areas of interest include Alzheimer's disease, Schizophrenia, Depression, and other neurological disorders. As of the latest available information up to October 2023, there are no specific recent major developments provided in the data for Suven Life Sciences Ltd. The company's efforts are directed towards innovation in drug development, which is a critical part of its business strategy.

Revenue

For the second quarter of fiscal year 2026 (Q2FY26), Suven Life Sciences Ltd reported a total income of ₹4.70 crores. This represents a significant quarter-over-quarter (QoQ) increase of 90.3% compared to the previous quarter, Q1FY26, where the total income was ₹2.47 crores. However, when compared year-over-year (YoY) to Q2FY25, where the total income was ₹6.61 crores, there is a decline of 28.9%. This fluctuation in revenue indicates variability in the company's income over these periods. The provided data does not elaborate on the specific sources of revenue or the factors contributing to these changes.

Profitability

In terms of profitability, Suven Life Sciences Ltd's performance for Q2FY26 shows a continued trend of operating losses. The company recorded a profit before tax of -₹77.31 crores, which is a deterioration compared to both Q1FY26 and Q2FY25, where the losses were -₹51.52 crores and -₹49.64 crores, respectively. This reflects a QoQ increase in losses by 50.1% and a YoY increase of 55.7%. Correspondingly, the profit after tax mirrors the profit before tax figures, as there was no tax recorded for these periods. The earnings per share (EPS) for Q2FY26 was -₹3.48, worsening from -₹2.36 in Q1FY26 and -₹2.27 in Q2FY25, indicating a 47.5% QoQ and 53.3% YoY increase in negative EPS values.

Operating Metrics

The total expenses for Q2FY26 amounted to ₹82.01 crores, which shows a significant QoQ increase of 51.9% from Q1FY26, where expenses were ₹53.99 crores. When compared to Q2FY25, where the expenses were ₹56.26 crores, there is a 45.8% YoY increase. Suven Life Sciences Ltd did not report any tax for the quarters in question, which is reflected in the unchanged tax figures across Q2FY26, Q1FY26, and Q2FY25. The trends in operating metrics highlight substantial increases in expenses, which have not been offset by the income growth, leading to increased losses in profitability measures. The financial data does not provide details on specific operational activities or initiatives that might have contributed to these financial outcomes.